MX371073B - Método para utilizar ciclodextrina. - Google Patents

Método para utilizar ciclodextrina.

Info

Publication number
MX371073B
MX371073B MX2014012200A MX2014012200A MX371073B MX 371073 B MX371073 B MX 371073B MX 2014012200 A MX2014012200 A MX 2014012200A MX 2014012200 A MX2014012200 A MX 2014012200A MX 371073 B MX371073 B MX 371073B
Authority
MX
Mexico
Prior art keywords
cellular
cyclodextrin
diabetes
cholesterol
relating
Prior art date
Application number
MX2014012200A
Other languages
English (en)
Spanish (es)
Other versions
MX2014012200A (es
Inventor
Fornoni Alessia
Merscher-Gomez Sandra
Original Assignee
L&F Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L&F Res Llc filed Critical L&F Res Llc
Publication of MX2014012200A publication Critical patent/MX2014012200A/es
Publication of MX371073B publication Critical patent/MX371073B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014012200A 2012-04-13 2013-04-12 Método para utilizar ciclodextrina. MX371073B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Publications (2)

Publication Number Publication Date
MX2014012200A MX2014012200A (es) 2015-06-17
MX371073B true MX371073B (es) 2020-01-15

Family

ID=49328287

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012200A MX371073B (es) 2012-04-13 2013-04-12 Método para utilizar ciclodextrina.
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020000205A MX392972B (es) 2012-04-13 2013-04-12 Metodo para utilizar ciclodextrina.

Country Status (8)

Country Link
US (4) US10195227B2 (enExample)
EP (2) EP2836221B1 (enExample)
JP (4) JP6491089B2 (enExample)
CN (2) CN104244956B (enExample)
CA (1) CA2870316C (enExample)
ES (1) ES2959119T3 (enExample)
MX (2) MX371073B (enExample)
WO (1) WO2013155485A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836221B1 (en) * 2012-04-13 2023-07-05 L&F Research LLC Method of using cyclodextrin
CN105611909B (zh) 2013-03-12 2020-09-15 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
EP3307278A4 (en) 2015-06-10 2018-06-13 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CN109982718A (zh) * 2016-09-19 2019-07-05 阿托恩波罗斯生命科学 基于环糊精的聚合物、方法、组合物及其应用
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
CN112996562A (zh) 2018-10-29 2021-06-18 赛克洛治疗股份有限公司 治疗阿尔茨海默病的方法
US11279774B2 (en) 2019-01-03 2022-03-22 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
EP4203974A4 (en) * 2020-08-27 2024-08-07 Beren Therapeutics P.B.C. METHOD FOR TREATING CARDIOVASCULAR DISEASES WITH CYCLODEXTRINS
WO2022047241A1 (en) * 2020-08-27 2022-03-03 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN116635007A (zh) * 2020-08-27 2023-08-22 贝伦治疗公益公司 用环糊精预防胆固醇结晶栓塞的方法
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
US20220260597A1 (en) * 2021-02-18 2022-08-18 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
CN116322710A (zh) * 2021-09-01 2023-06-23 株式会社雷纳图斯 包括γ-环糊精聚合物的药物组合物以及其用途
KR20240160120A (ko) 2022-02-18 2024-11-08 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6756504B2 (en) 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
WO2004016101A2 (en) 2002-08-19 2004-02-26 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
JP2004323443A (ja) 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
WO2005000217A2 (en) * 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
JP5069130B2 (ja) 2005-01-27 2012-11-07 エリモス・ファーマスーティカルズ・エルエルシー Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
UA95310C2 (ru) * 2006-10-20 2011-07-25 Айкос Корпорейшен Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
CA2740003A1 (en) * 2008-10-10 2010-04-15 Limerick Biopharma, Inc. Pyrone analogs for therapeutic treatment
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
EP2352502A4 (en) 2008-11-06 2012-12-26 Univ Miami LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
WO2011043630A2 (ko) 2009-10-08 2011-04-14 (주)송호바이오메드 고 수용성 ２-하이드록시프로필-베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
WO2011057172A1 (en) 2009-11-06 2011-05-12 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10052345B2 (en) * 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
EP2836221B1 (en) * 2012-04-13 2023-07-05 L&F Research LLC Method of using cyclodextrin

Also Published As

Publication number Publication date
JP2018203747A (ja) 2018-12-27
ES2959119T3 (es) 2024-02-20
US20190262385A1 (en) 2019-08-29
JP6491089B2 (ja) 2019-03-27
EP2836221A2 (en) 2015-02-18
JP2015512949A (ja) 2015-04-30
US10195227B2 (en) 2019-02-05
JP2023178518A (ja) 2023-12-15
MX2014012200A (es) 2015-06-17
MX392972B (es) 2025-03-21
JP2021155436A (ja) 2021-10-07
MX2020000205A (es) 2022-06-06
CA2870316A1 (en) 2013-10-17
WO2013155485A2 (en) 2013-10-17
EP2836221A4 (en) 2016-07-27
EP4299121A2 (en) 2024-01-03
CN104244956B (zh) 2020-04-17
US20230338412A1 (en) 2023-10-26
CN111419870A (zh) 2020-07-17
WO2013155485A3 (en) 2013-12-19
EP2836221B1 (en) 2023-07-05
US10980828B2 (en) 2021-04-20
CA2870316C (en) 2022-04-19
EP4299121A3 (en) 2024-07-24
US20150065457A1 (en) 2015-03-05
US20210228616A1 (en) 2021-07-29
CN104244956A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2020000205A (es) Metodo para utilizar ciclodextrina.
MX346428B (es) Metodo para tratar eccema.
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
WO2013003601A9 (en) Method for treating phytophotodermatitis
EA201491386A1 (ru) Соединения, ингибирующие металлоферменты
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EP2542584B8 (en) Methods for treating pancreatic cancer
MX2015012983A (es) Metodo para producir un conjugado de inmunoligando/carga util por medio de una enzima de transpeptidasa especifica de una secuencia.
EP2672967A4 (en) COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATING THEREFOR
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
EA201490038A1 (ru) Соединения, ингибирующие металлоферменты
WO2012149472A9 (en) Methods, compositions, and kits for treating and preventing neurological conditions
MY202135A (en) Uses of neuroactive compounds
UY34280A (es) Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa.
WO2012177925A8 (en) Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
MX2014006157A (es) Moduladores mejoradores de la actividad de hec1 y metodos para los mismos.
MY164954A (en) Method for purifying organic diphosphite compounds
BR112015013152A2 (pt) composição para tratamento de uma formação subterrânea , método para tratar uma formação subterrânea , e método para reduzir a viscosidade de óleo cru.
EP2862936A4 (en) Oxidoreductase reaction control and use thereof
WO2012134626A3 (en) Processes for enzymatic refining of pretreated cellulosic material for saccharification
MX2015007778A (es) Prediccion de bioactivacion molecular.
WO2011083483A3 (en) Method for treatment of inflammatory disease and disorder
PH12013500275A1 (en) Novel trpv3 modulators

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: L&F RESEARCH LLC

FG Grant or registration